HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ICCM
IceCure Medical Ltd
ICCM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ICCM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ICCM's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ICCM PE Valuation
ICCM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ICCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ICCM's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ICCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.76 | +$1.62 |
| Q1 2026 | -$7.02 | +$1.52 |
| Q4 2025 | -$7.15 | +$1.79 |
| Q3 2025 | -$7.82 | +$0.77 |
| Q2 2025 | -$8.38 | +$0.47 |
| Q1 2025 | -$8.54 | +$0.99 |
| Q4 2024 | -$8.94 | +$0.67 |
| Q3 2024 | -$8.59 | +$2.25 |
ICCM has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ICCM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ICCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $907K | +73% |
| Q1 2026 | $911K | +26% |
| Q4 2025 | $1.3M | +46% |
| Q3 2025 | $850K | +28% |
| Q2 2025 | $525K | -48% |
| Q1 2025 | $725K | -2.4% |
| Q4 2024 | $875K | -30% |
| Q3 2024 | $662K | +102% |
ICCM's revenue is recovering but still below its 2021 peak: $907,000 last quarter, up 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 488% | +1133 points |
| Q1 2026 | -466% | +38 points |
| Q4 2025 | -330% | +188 points |
| Q3 2025 | -2108% | -1460 points |
| Q2 2025 | -645% | -326 points |
| Q1 2025 | -504% | -13 points |
| Q4 2024 | -517% | -245 points |
| Q3 2024 | -648% | +612 points |
ICCM has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ICCM on cash generation, producing positive trailing cash flow while its opponent burns cash.
ICCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | -$1.1M |
| Q1 2026 | -$4.3M | -$277K |
| Q4 2025 | -$5.5M | -$1.3M |
| Q3 2025 | -$2.7M | +$477K |
| Q2 2025 | -$2.8M | -$464K |
| Q1 2025 | -$4M | -$1.2M |
| Q4 2024 | -$4.2M | -$1.6M |
| Q3 2024 | -$3.2M | +$209K |
ICCM has burned cash in almost every quarter: −$16M over the past year, against −$14M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ICCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ICCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +634K shares |
| 1 year | +58% | +1.1M shares |
| 3 years | +103% | +1.6M shares |
| 5 years | +223% | +2.1M shares |
| Available history | +554% | +2.6M shares |
ICCM has 3M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ICCM hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ICCM Net Leverage
ICCM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ICCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.3 | Oversold |
| Stochastic | 1.5 | Oversold |
ICCM's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ICCM PE vs Healthcare Sector
ICCM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ICCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 36% below |
| 20 week MA | $2.23 | 69% below |
| 50 week MA | $9.11 | 92% below |
| 100 week MA | $20.4 | 97% below |
| 200 week MA | $25.3 | 97% below |
ICCM is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ICCM on returns for 2026, with the stronger performance.
ICCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $331.5 | $85.2 | -74% |
| 2022 | $85.2 | $42.0 | -51% |
| 2023 | $42.0 | $32.1 | -24% |
| 2024 | $32.1 | $33.6 | +4.7% |
| 2025 | $33.6 | $19.9 | -41% |
| 2026 YTD | $19.9 | $0.70 | -96% |
ICCM has finished lower in four of the last five years. It's down 96% so far in 2026.